Current review panels

Review panels are composed for specific competitions and membership will depend on the expertise needed. Please select the appropriate competition for information on a given panel.


Panel membership will be posted once funding announcements are made. 

For competitions with an LOI stage - panels may be reduced between stages depending on expertise required to review the full applications. Panel members participating in the LOI review only will be marked with an *.

For competitions with multiple panels – applicants indicate their panel recommendation, however, final panel selection will be determined by the panel chairs and CCS based on the panel with the most appropriate expertise.

Innovation Grant and Innovation to Impact Grant panels

I1a - Biomarkers and Genomics

Including genomics, proteomics, metabolomics (and other ‘omics’), high-throughput sequencing, bioinformatics, diagnostic, prognostic and predictive biomarkers, circulating tumour cells.

Panel meeting: May 14, 2019

Paul Boutros, PhD (Chair) University of California, Los Angeles
Los Angeles, CA


I1b - Gene Regulation & Cell Biology

Including mechanisms of transcriptional control, epigenetics, chromatin structure and function, translational control, RNA biology, post-translational modifications, telomere function, DNA damage and repair, organellar biology, model organisms, angiogenesis, cell migration, cell invasion, tumour environment.

Panel meeting: May 2 & 3, 2019

Peter Greer, PhD (Chair) Queen's University
Kingston, ON


I2 - Imaging and Technology Development

Including platform and tool development, systems biology, magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasound, computer tomography (CT), radiobiology, radiotherapy, photodynamic therapy (PDT), optical imaging, microfluidics, nanotechnology.

Panel meeting: May 28, 2019

Sabine Mai, PhD (Chair) University of Manitoba
Winnipeg, MB


I3 - Immunology, Signalling and Stem Cells

Including metastasis, hormone-sensitive pathways, growth-factor mediated signalling, immunotherapies, viral therapeutics, cancer stem cells, signal transduction, innate immunity and infection, tumour antigens, immune surveillance, hematopoiesis.

Panel meeting: May 7 & 8, 2019

Kevin Kane, PhD (Chair) University of Alberta
Edmonton, AB


I4 - Novel Therapeutics

Including drug candidates, rational drug design, hit and target validation, compound screening, medicinal chemistry, pharmacology, drug delivery systems, drug transport, drug resistance, combination therapies and pharmacogenomics.

Panel meeting: April 25 & 26, 2019

Michael Tyers, PhD (Chair) Université de Montréal
Montréal, QC


I5 - Prevention and Quality of Life 

Including epidemiology, prevention interventions, lifestyle and environmental risk factors, health economics, health services, quality of life, survivorship, palliative care, psychosocial issues, knowledge translation and exchange.

Panel meeting: April 30, 2019

Patricia Parker, PhD (Chair) Memorial Sloan Kettering Cancer Center
New York, NY


Impact Grant panel

LOI review teleconference: June 1, 2018

Panel meeting: November 7, 2018

Shoukat Dedhar, PhD (Co-Chair) BC Cancer Agency
Vancouver, BC
Lillian Sung, MD/PhD (Co-Chair) The Hospital for Sick Children
Toronto, ON
Stephane Angers, PhD University of Toronto
Toronto, ON
Rebecca Auer, MD Ottawa Hospital Research Institute
Ottawa, ON
Mick Bhatia, PhD McMaster University
Hamilton, ON
*Peter Black, MD University of British Columbia
Vancouver, BC
Darren Brenner, PhD University of Calgary
Calgary, AB
*Karen Emmons, PhD Harvard University
Boston, MA
Trang Hoang, PhD IRIC
Montreal, QC
Philip Kim, PhD
University of Toronto
Toronto, ON
Robert Kerbel, PhD Sunnybrook Research Institute
Toronto, ON 
Calum MacAulay, PhD BC Cancer Agency
Vancouver, BC 
Sylvain Meloche, PhD University of Montreal
Montreal, QC
*Anne-Marie Mes-Masson, PhD Centre de recherche du CHUM
Montreal, QC
*Karen Mossman, PhD McMaster University
Hamilton, ON
Claude Perreault, MD IRIC
Montreal, QC
*Janusz Rak, MD/PhD McGill University
Montreal, QC
James Rutka, MD/PhD The Hospital for Sick Children
Toronto, ON 
*Poul Sorensen, PhD BC Cancer Agency
Vancouver, BC
Bradly Wouters, PhD Princess Margaret Cancer Centre - UHN
Toronto, ON
*Jeffrey Wrana, PhD Mount Sinai Hospital
Toronto, ON
*Li Zhang, MD/PhD The Toronto General Hospital
Toronto, ON
*Camilla Zimmermann, MD/PhD Princess Margaret Cancer Centre - UHN
Toronto, ON
Jason Pole, PhD (Scientific Officer) Pediatric Oncology Group of Ontario
Toronto, ON
Sheila Singh, PhD (Scientific Officer)
McMaster University
Hamilton, ON 
Valerie Gauvin (Community Representative)
Canadian Cancer Society - BC/Yukon
Joel Finlay (Community Representative)
Canadian Cancer Society - BC/Yukon 

Last modified on: April 11, 2019